Skip to main content
. 2019 Oct 25;20(21):5329. doi: 10.3390/ijms20215329

Figure 8.

Figure 8

Association of mRNA expression of ADORA2A and ADORA2B with overall survival (A,C) and disease/progression (D/P)-free survival (B,D) in pancreatic adenocarcinoma patients. (A) High (n = 13) and low (n = 165) expression of ADORA2A (P = 0.0302). (B) High (n = 10) and low (n = 128) expression of ADORA2A (P = 0.0104). (C) Median survival time was 12.5 and 20.6 months with high (n = 12) and low (n = 166) expression of ADORA2B, respectively (P = 0.166). (D) Median disease-free survival time was 8.5 and 17.1 months with high (n = 10) and low (n = 128) expression of ADORA2B, respectively (P = 0.0125).